Mylan NV

Building 4, Trident Place,
Hertfordshire, AL10 9UL
United Kingdom,
+44 1707 853000
www.mylan.com

Mylan NV is a generic and specialty pharmaceutical company. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Mylan NV was established in 1961 and is headquartered in Hertfordshire, England.

M&A Summary

Buy vs Sell

Year ≤ '12 '13 '14 '15 '16 '17 T
Buy (0.8/yr) # 5 1 - 2 1 - 9
vol $6.1B $1.8B $6.1B $1.0B $14.9B
Sell (0.0/yr) # - - - - - - 0
  9

Top M&A Advisors

Financial Deals
Sign-up to View
1
Sign-up to View
1
Sign-up to View
1
Legal Deals
Sign-up to View
2
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Merck Generics
$5.5B (2007-05-12)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View

According to our data here at Mergr, Mylan NV has acquired 9 companies, including 4 in the last 5 years. A total of 2 acquisitions came from private equity firms.

Mylan NV’s largest acquisition to date was in 2007, when it acquired Merck Generics for $5.5B. Mylan NV has acquired in 3 different US states, and 4 countries. The Company’s most targeted sectors include life science (67%) and medical products (34%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 23 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Mylan NV’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 113K M&A Transactions
  • 123K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.